Is NeoGenomics (NEO) overvalued or fairly valued?

MarketChacha shows NeoGenomics's valuation in context — a forward P/E of about 47.9, a price-to-book of about 2.7 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is NeoGenomics's revenue?

NeoGenomics reported revenue of $727.3M for FY2025, with net profit of $-108.0M, per official filings.

What is the share price of NeoGenomics (NEO)?

NeoGenomics last traded at $16.75 (+2.0% on the day), as of 10/20/2026 — a delayed quote shown for education, not investment advice.

NeoGenomics

NEO · NYSE · Healthcare · United States

Snapshot

TickerNEO

ExchangeNYSE

SectorHealthcare

IndustryDiagnostics & Research

CountryUnited States

Employees2,500

HeadquartersFort Myers, United States

Websitewww.neogenomics.com

Filings tracked21

About NeoGenomics

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Who owns it

Insiders2.1%
Institutions97.9%
Public & other0.0%

373 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.16.24%
First Light Asset Management, LLC9.56%
First Trust Advisors LP7.87%
Greenhouse Funds, LLLP6.67%
Vanguard Portfolio Management LLC6.27%
Vanguard Capital Management LLC4.49%
State Street Corporation4.17%
Nomura Asset Management International Inc3.92%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Latest ROE of -12.9% is on the low side — the business earns a modest return on shareholder capital.

Net margin trend-14.9% → -14.9%

Margin has held broadly steady over the period — stable profitability.

Return on equity-12.9%

Latest ROE of -12.9% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $210.2M · EPS 0.07

Est. earnings growth +16.7%

Next fiscal year

Rev $885.4M · EPS 0.34

Est. earnings growth +83.0%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$727.3M

Net margin

-14.9%

ROE

-12.9%

Revenue CAGR (2y)

+10.9%

Net profit (FY2025)

$-108.0M

Ask MarketChacha about NEO

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin	ROE
FY2025	$727.3M	$-108.0M	-14.9%	-12.9%
FY2024	$660.6M	$-78.7M	-11.9%	-8.7%
FY2023	$591.6M	$-88.0M	-14.9%	-9.3%

Quarterly

Period	Revenue	Net profit	Net margin
2026Q2	$201.7M	$2.2M	1.1%
2026Q1	$186.7M	$-17.1M	-9.2%
2025Q3	$187.8M	$-27.1M	-14.4%
2025Q2	$181.3M	$-45.1M	-24.9%
2025Q1	$168.0M	$-25.9M	-15.4%
2024Q3	$167.8M	$-17.7M	-10.5%
2024Q2	$164.5M	$-18.6M	-11.3%
2024Q1	$156.2M	$-27.1M	-17.3%
2023Q3	$152.0M	$-18.5M	-12.2%
2023Q2	$146.9M	$-24.3M	-16.6%
2023Q1	$137.2M	$-30.8M	-22.4%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Executive/director change
SEC8/11/2026material
8-K — Results of operations, Exhibits
SEC7/28/2026material
10-Q filing
SEC7/28/2026
8-K/A — Reg FD disclosure, Other events, Exhibits
SEC7/22/2026
8-K — Reg FD disclosure, Other events, Exhibits
SEC7/20/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC6/25/2026material
8-K — Material agreement, Material financial obligation, Unregistered equity sale, Other events, Exhibits
SEC6/22/2026material
8-K — Other events, Exhibits
SEC6/17/2026material
8-K — Other events, Exhibits
SEC6/15/2026material
8-K — Executive/director change, Shareholder vote results, Exhibits
SEC5/22/2026material
8-K — Results of operations, Exhibits
SEC4/28/2026material
10-Q filing
SEC4/28/2026
8-K — Results of operations, Exhibits
SEC2/17/2026material
10-K filing
SEC2/17/2026
8-K — Results of operations, Executive/director change, Exhibits
SEC1/12/2026material

2025

8-K — Executive/director change, Exhibits
SEC12/30/2025material
8-K — Results of operations, Exhibits
SEC10/28/2025material
10-Q filing
SEC10/28/2025
8-K — Executive/director change
SEC8/8/2025material
8-K — Results of operations, Exhibits
SEC7/29/2025material
10-Q filing
SEC7/29/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.